- Report
- May 2025
- 191 Pages
Global
From €3111EUR$3,545USD£2,692GBP
€3457EUR$3,939USD£2,991GBP
- Report
- February 2025
- 200 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- July 2025
- 208 Pages
Global
From €5134EUR$5,850USD£4,442GBP
- Report
- June 2025
- 400 Pages
Global
From €4343EUR$4,949USD£3,758GBP
Daclatasvir is a direct-acting antiviral drug used to treat chronic hepatitis C virus (HCV) infection. It is a NS5A inhibitor, which works by blocking the replication of the virus. Daclatasvir is used in combination with other antiviral drugs to treat HCV infection in adults and children. It is also used to treat liver and kidney disorders caused by HCV infection.
Daclatasvir is available in tablet form and is taken orally. It is usually taken once a day with or without food. The dosage and duration of treatment depend on the type of HCV infection and the patient's response to treatment. Common side effects of daclatasvir include headache, fatigue, nausea, and diarrhea.
Daclatasvir is marketed by several companies, including Bristol-Myers Squibb, Gilead Sciences, and AbbVie. It is also available in generic form from several generic drug manufacturers. Show Less Read more